KE

Katie Ellias

Managing Director at T1D Fund

Greater Boston

Overview 

Katie Ellias is a Managing Director at T1D Fund, investing in various sectors including medical devices and biotechnology. She serves on the board of multiple companies, such as SAb Biotherapeutics and DiogenX, and has invested in successful ventures like Veralox Therapeutics and Biolinq. With an MBA from The Wharton School and a background in venture capital, Katie has excelled in leading cross-functional teams, commercializing products, and driving successful mergers and acquisitions in the healthcare industry. Her current role at T1D Fund showcases her expertise in venture philanthropy and her ability to identify and support innovative startups in the Boston area.

Work Experience 

F⎮

FACCNE ⎮ French-American Chamber of Commerce, New England

  • Board Member

    2025 - Current

SB

SAb Biotherapeutics

  • Board Member

    2023

SAB Biotherapeutics is a clinical-stage biopharmaceutical development company.

Raised $186,320,000.00 from Marshall Wace, RA Capital Management, Commodore Capital, Sessa Capital, RTW Investments, JDRF T1D Fund, Biotechnology Value Fund and T. Denny Sanford.

sab.bio
WH

WHARTON HEALTH CARE MANAGEMENT ALUMNI ASSOCIATION

  • Board Member

    2021

TF

T1D Fund

  • Managing Director

    2018 - 2024

    The Fund is a venture philanthropy fund committed to accelerating life-changing solutions to treat, prevent, and cure type 1 diabetes (T1D) through catalytic equity investments. While independently managed, the Fund is affiliated with JDRF, the leading global organization funding T1D research. Through its investments in partnership with private capital, including venture capital, corporations and foundations, the T1D Fund seeks to attract the private investment necessary to advance cures and therapies into the hands of those living with T1D. The T1D Fund invests in areas strategically aligned with JDRF, with an exclusive focus on supporting the best commercial opportunities. The T1D Fund reinvests any realized gains into new investments to further its mission.

S

Seraxis

  • Board Observer

    2021 - 2024

Seraxis is a privately owned biotechnology company.

Raised $40,400,000.00 from Maryland Stem Cell Research Fund (MSCRF).

seraxis.com
D

DiogenX

  • Board Member

    2020 - 2024

iT

i2o Therapeutics

  • Board Observer

    2020 - 2024

I2o Therapeutics is a biotech company that develops safe and effective oral formulations of therapies.

Raised $90,439,921.00 from Viva BioInnovator.

i2obio.com
B

Biolinq

  • Board Observer

    2019 - 2024

Biolinq develops a wearable biosensor platform that is capable of measuring blood level information.

Raised $254,251,237.00 from Niterra Ventures, Taisho Pharmaceutical Holdings, Features Capital, Aphelion Capital, Alpha Wave Ventures, Global Health Investment Corporation, Senvest Management, AXA Investment Managers, Pegasus Tech Ventures and RiverVest.

biolinq.com
VT

VERALOX Therapeutics

  • Board Member

    2019 - 2024

Veralox Therapeutics develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type one diabetes.

Raised $47,460,000.00 from Hatteras Venture Partners, JDRF T1D Fund, Genesys Capital, Pappas Capital, NYBC Ventures and Sanofi Ventures.

veralox.com
EP

Enthera Pharmaceuticals

  • Board Observer

    2018 - 2024

Education 

Investments 

Veralox Therapeutics

Seed

Total funding: $46M

Jaguar Gene Therapy

Series Unknown

Total funding: $140M

Biolinq

Series A

Total funding: $110M

DiogenX

Seed

Total funding: $42M

Articles About Katie

Relevant Websites